Skip to main content

Advertisement

SpringerLink
Log in

The medical management of opioid dependence in HIV primary care settings

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Injecting drug use is a common mode of transmission among persons with HIV/AIDS. Many HIV-infected patients meet diagnostic criteria for opioid dependence, a chronic and relapsing brain disorder. Most HIV providers, however, receive little training in substance use disorders. Opioid agonist therapy (OAT) has a stabilizing effect on opioid-dependent patients and is associated with greater acceptance of antiretroviral (ARV) therapy, higher ARV adherence, and greater engagement in HIVrelated health care. Although methadone maintenance has been the OAT gold standard, methadone is available for the treatment of opioid dependence only in strictly regulated narcotic treatment programs. Buprenorphine, a partial opioid agonist approved for the office-based treatment of opioid dependence in 2002, may result in better health and substance use treatment outcomes for patients with HIV disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Centers for Disease Control and Prevention: HIV/AIDS Surveillance Report, 2003, vol. 15. Atlanta: US Department of Health and Human Services; 2004.

    Google Scholar 

  2. San Francisco Department of Public Health: HIV/AIDS Epidemiology Annual Report, 2004. San Francisco; 2005.

  3. Shapiro MF, Morton SC, McCaffrey DF, et al.: Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 1999, 281:2305–2315.

    Article  PubMed  CAS  Google Scholar 

  4. Celentano DD, Vlahov D, Cohn S, et al.: Self-reported antiretroviral therapy in injection drug users. JAMA 1998, 280:544–546.

    Article  PubMed  CAS  Google Scholar 

  5. Bassetti S, Battegay M, Furrer H, et al.: Why is highly active antiretroviral therapy (HAART) not prescribed or discontinued? Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 1999, 21:114–119.

    PubMed  CAS  Google Scholar 

  6. Loughlin A, Metsch L, Gardner L, et al.: Provider barriers to prescribing HAART to medically-eligible HIV-infected drug users. AIDS Care 2004, 16:485–500.

    Article  PubMed  CAS  Google Scholar 

  7. Wood E, Hogg RS, Yip B, et al.: Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS 2005, 19:1189–1195.

    Article  PubMed  Google Scholar 

  8. Ding L, Landon BE, Wilson IB, et al.: Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users. Arch Intern Med 2005, 165:618–623.

    Article  PubMed  Google Scholar 

  9. Miller NS, Sheppard LM, Colenda CC, Magen J: Why physicians are unprepared to treat patients who have alcohol-and drug-related disorders. Acad Med 2001, 76:410 -418.

    Article  PubMed  CAS  Google Scholar 

  10. Fleming M, Barry K, Davis A, et al.: Medical education about substance abuse: changes in curriculum and faculty between 1976 and 1992. Acad Med 1994, 69:362–369.

    Article  PubMed  CAS  Google Scholar 

  11. Merrill JO, Rhodes LA, Deyo RA, et al.: Mutual mistrust in the medical care of drug users: the keys to the "narc" cabinet. J Gen Intern Med 2002, 17:327–333.

    PubMed  Google Scholar 

  12. Saitz R, Friedmann PD, Sullivan LM, et al.: Professional satisfaction experienced when caring for substance-abusing patients: faculty and resident physician perspectives. J Gen Intern Med 2002, 17:373–376.

    PubMed  Google Scholar 

  13. Kreek MJ, Bart G, Lilly C, et al.: Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. Pharmacol Rev 2005, 57:1–26. Detailed and thorough review of the genetic basis of opiate and cocaine use and their treatments.

    Article  PubMed  CAS  Google Scholar 

  14. de Ridder M: Heroin: new facts about an old myth. J Psychoactive Drugs 1994, 26:65–68.

    PubMed  Google Scholar 

  15. Jaffe JH, O‘Keeffe C: From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend 2003, 70:S3-S11.

    Article  PubMed  Google Scholar 

  16. Ciccarone D, Bourgois P: Explaining the geographical variation of HIV among injection drug users in the United States. Subst Use Misuse 2003, 38:2049–2063.

    Article  PubMed  CAS  Google Scholar 

  17. Passaro DJ, Werner SB, McGee J, et al.: Wound botulism associated with black tar heroin among injecting drug users. JAMA 1998, 279:859–863.

    Article  PubMed  CAS  Google Scholar 

  18. Substance Abuse and Mental Health Services Administration: Overview of findings from the 2003 National Survey on Drug Use and Health. In NSDUH Series H-24, DHHS Publication No SMA 04-3963. Rockville, MD: US Department of Health and Human Services; 2004.

    Google Scholar 

  19. Compton WM, Volkow ND: Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend 2006, 81:103–107.

    Article  PubMed  Google Scholar 

  20. Substance Abuse and Mental Health Services Administration: Nonmedical oxycodone users: a comparison with heroin users. In The National Survey on Drug Use and Health. Rockville, MD: US Department of Health and Human Services; 2005.

    Google Scholar 

  21. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA 1998, 280:1936–1943.

  22. Stimmel B, Kreek MJ: Neurobiology of addictive behaviors and its relationship to methadone maintenance. Mt Sinai J Med 2000, 67:375–380.

    PubMed  CAS  Google Scholar 

  23. Kreek MJ, Nielsen DA, Butelman ER, LaForge KS: Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. Nat Neurosci 2005, 8:1450–1457.

    Article  PubMed  CAS  Google Scholar 

  24. McLellan AT, Lewis DC, O‘Brien CP, Kleber HD: Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689–1695.

    Article  PubMed  CAS  Google Scholar 

  25. Nestler EJ, Aghajanian GK: Molecular and cellular basis of addiction. Science 1997, 278:58–63.

    Article  PubMed  CAS  Google Scholar 

  26. Koob GF, Sanna PP, Bloom FE: Neuroscience of addiction. Neuron 1998, 21:467–476.

    Article  PubMed  CAS  Google Scholar 

  27. Kreek MJ, Koob GF: Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend 1998, 51:23–47.

    Article  PubMed  CAS  Google Scholar 

  28. Sulkowski MS, Thomas DL: Hepatitis C in the HIVinfected person. Ann Intern Med 2003, 138:197–207.

    PubMed  Google Scholar 

  29. Perlman DC, Salomon N, Perkins MP, et al.: Tuberculosis in drug users. Clin Infect Dis 1995, 21:1253.

    PubMed  CAS  Google Scholar 

  30. Boschini A, Smacchia C, Di Fine M, et al.: Communityacquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. Clin Infect Dis 1996, 23:107–113.

    PubMed  CAS  Google Scholar 

  31. Gordon RJ, Lowy FD: Bacterial infections in drug users. N Engl J Med 2005, 353:1945–1954.

    Article  PubMed  CAS  Google Scholar 

  32. Hulse GK, English DR, Milne E, Holman CDJ: The quantification of mortality resulting from the regular use of illicit opiates. Addiction 1999, 94:221–229.

    Article  PubMed  CAS  Google Scholar 

  33. Substance Abuse and Mental Health Services Administration: Emergency department trends from the Drug Abuse Warning Network, final estimates 1995–2002. In DAWN Series: D-24, DHHS Publication No (SMA) 03-3780. Rockville, MD: US Department of Health and Human Services; 2003.

    Google Scholar 

  34. Substance Abuse and Mental Health Services Administration: Drug Abuse Warning Network, 2003: area profiles of drug-related mortality. In DAWN Series D-27, DHHS Publication No (SMA) 05-4023. Rockville, MD: US Department of Health and Human Services; 2005.

    Google Scholar 

  35. Gossop M, Stewart D, Treacy S, Marsden J: A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction 2002, 97:39–47.

    Article  PubMed  Google Scholar 

  36. Degenhardt L, Hall W, Warner-Smith M: Using cohort studies to estimate mortality among injecting drug users that is not attributable to AIDS. Sex Transm Infect 2006, 82:iii56–63.

    Article  PubMed  Google Scholar 

  37. Sporer KA: Acute heroin overdose. Ann Intern Med 1999, 130:584–590.

    PubMed  CAS  Google Scholar 

  38. Wang C, Vlahov D, Galai N, et al.: The effect of HIV infection on overdose mortality. AIDS 2005, 19:935–942.

    Article  PubMed  Google Scholar 

  39. Krantz MJ, Mehler PS: Treating opioid dependence. Growing implications for primary care. Arch Intern Med 2004, 164:277–288.

    Article  PubMed  CAS  Google Scholar 

  40. Ball J, Corty E, Bond H, Myers C, Tommasello A: The reduction of intravenous heroin use, non-opiate abuse and crime during methadone maintenance treatment: further findings. NIDA Res Monogr 1988, 81:224–230.

    PubMed  CAS  Google Scholar 

  41. Caplehorn JR, Ross MW: Methadone maintenance and the likelihood of risky needle-sharing. Int J Addict 1995, 30:685–698.

    PubMed  CAS  Google Scholar 

  42. Gibson DR, Flynn NM, McCarthy JJ: Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 1999, 13:1807–1818.

    Article  PubMed  CAS  Google Scholar 

  43. Moss AR, Vranizan K, Gorter R, et al.: HIV seroconversion in intravenous drug users in San Francisco, 1985–1990. AIDS 1994, 8:223–231.

    Article  PubMed  CAS  Google Scholar 

  44. Metzger DS, Woody GE, McLellan AT, et al.: Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 1993, 6:1049–1056.

    PubMed  CAS  Google Scholar 

  45. Gossop M, Trakada K, Stewart D, Witton J: Reductions in criminal convictions after addiction treatment: 5-year follow-up. Drug Alcohol Depend 2005, 79:295–302.

    Article  PubMed  Google Scholar 

  46. Brugal MT, Domingo-Salvany A, Puig R, Barrio G, et al.: Evaluating the impact of methadone maintenance programmes on mortality due to overdose and aids in a cohort of heroin users in Spain. Addiction 2005, 100:981–989.

    Article  PubMed  CAS  Google Scholar 

  47. Weber R, Ledergerber B, Opravil M, et al.: Progression of HIV infection in misusers of injected drugs who stop injecting or follow a programme of maintenance treatment with methadone. BMJ 1990, 301:1362–1365.

    PubMed  CAS  Google Scholar 

  48. Laine C, Hauck WW, Turner BJ: Outpatient patterns of care and longitudinal intensity of antiretroviral therapy for HIV-infected drug users. Med Care 2002, 40:976–995.

    Article  PubMed  Google Scholar 

  49. Laine C, Hauck WW, Gourevitch MN, et al.: Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA 2001, 285:2355–2362.

    Article  PubMed  CAS  Google Scholar 

  50. Fiellin DA, O‘Connor PG: New federal initiatives to enhance the medical treatment of opioid dependence. Ann Intern Med 2002, 137:688–692.

    PubMed  Google Scholar 

  51. Jasinski DR, Pevnick JS, Griffith JD: Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978, 35:501–516.

    PubMed  CAS  Google Scholar 

  52. Bickel WK, Stitzer ML, Bigelow GE, et al.: Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J Pharmacol Exp Ther 1988, 247:47–53.

    PubMed  CAS  Google Scholar 

  53. Chiang CN, Hawks RL: Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend 2003, 70:S39-S47.

    Article  PubMed  CAS  Google Scholar 

  54. Marsch LA, Bickel WK, Badger GJ, Jacobs EA: Buprenorphine treatment for opioid dependence: the relative efficacy of daily, twice and thrice weekly dosing. Drug Alcohol Depend 2005, 77:195–204.

    Article  PubMed  CAS  Google Scholar 

  55. Lange WR, Fudala PJ, Dax EM, Johnson RE: Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend 1990, 26:19–28.

    Article  PubMed  CAS  Google Scholar 

  56. Petry NM, Bickel WK, Piasecki D, et al.: Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000, 9:265–269.

    Article  PubMed  CAS  Google Scholar 

  57. Berson A, Gervais A, Cazals D, et al.: Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001, 34:346–350.

    Article  PubMed  CAS  Google Scholar 

  58. Herve S, Riachi G, Noblet C, et al.: Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol Hepatol 2004, 16:1033–1037.

    Article  PubMed  CAS  Google Scholar 

  59. Johnson RE, Jones HE, Jasinski DR, et al.: Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 2001, 63:97–103.

    Article  PubMed  CAS  Google Scholar 

  60. Jones HE, Johnson RE, Jasinski DR, et al.: Buprenorphine versus methadone in the treatment of pregnant opioiddependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005, 79:1–10.

    Article  PubMed  CAS  Google Scholar 

  61. Cowan A, Doxey JC, Harry EJ: The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br J Pharmacol 1977, 60:547–554.

    PubMed  CAS  Google Scholar 

  62. Sporer KA: Buprenorphine: a primer for emergency physicians. Ann Emerg Med 2004, 43:580–584.

    Article  PubMed  Google Scholar 

  63. Auriacombe M, Franques P, Tignol J: Deaths attributable to methadone vs buprenorphine in France. JAMA 2001, 285:45.

    Article  PubMed  CAS  Google Scholar 

  64. Reynaud M, Petit G, Potard D, Courty P: Six deaths linked to concomitant use of buprenorphine and benzodiazepines. Addiction 1998, 93:1385–1392.

    Article  PubMed  CAS  Google Scholar 

  65. Tracqui A, Kintz P, Ludes B: Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J Anal Toxicol 1998, 22:430–434.

    PubMed  CAS  Google Scholar 

  66. Stoller KB, Bigelow GE, Walsh SL, Strain EC: Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology 2001, 154:230.

    Article  PubMed  CAS  Google Scholar 

  67. Johnson RE, Eissenberg T, Stitzer ML, et al.: A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995, 40:17–25.

    Article  PubMed  CAS  Google Scholar 

  68. Krook AL, Brors O, Dahlberg J, et al.: A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction 2002, 97:533–542.

    Article  PubMed  CAS  Google Scholar 

  69. Johnson RE, Jaffe JH, Fudala PJ: A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992, 267:2750–2755.

    Article  PubMed  CAS  Google Scholar 

  70. Johnson RE, Chutuape MA, Strain EC, et al.: A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000, 343:1290 -1297.

    Article  PubMed  CAS  Google Scholar 

  71. Barnett PG, Zaric GS, Brandeau ML: The cost-effectiveness of buprenorphine maintenance therapy for opiate addiction in the United States. Addiction 2001, 96:1267–1278.

    Article  PubMed  CAS  Google Scholar 

  72. O‘Connor PG, Oliveto AH, Shi JM, et al.: A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med 1998, 105:100–105.

    Article  PubMed  CAS  Google Scholar 

  73. Fudala PJ, Bridge TP, Herbert S, et al.: Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003, 349:949–958.

    Article  PubMed  CAS  Google Scholar 

  74. Herget G: Methadone and buprenorphine added to the WHO list of essential medicines. HIV AIDS Policy Law Rev 2005, 10:23–24.

    PubMed  Google Scholar 

  75. Moatti JP, Carrieri MP, Spire B, et al.: Adherence to HAART in French HIV-infected injecting drug users: the contribution of buprenorphine drug maintenance treatment. The Manif 2000 study group. AIDS 2000, 14:151–155.

    Article  PubMed  CAS  Google Scholar 

  76. Carrieri MP, Rey D, Loundou A, et al.: Evaluation of buprenorphine maintenance treatment in a French cohort of HIV-infected injecting drug users. Drug Alcohol Depend 2003, 72:13–21.

    Article  PubMed  CAS  Google Scholar 

  77. Carrieri MP, Vlahov D, Dellamonica P, et al.: Use of buprenorphine in HIV-infected injection drug users: negligible impact on virologic response to HAART. The Manif-2000 Study Group. Drug Alcohol Depend 2000, 60:51–54.

    Article  PubMed  CAS  Google Scholar 

  78. Basu S, Smith-Rohrberg D, Bruce RD, Altice FL: Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis 2006, 42:716–721. eview of the advantages and disadvantages of four models that may be used to integrate buprenorphine into HIV primary care settings.

    Article  PubMed  Google Scholar 

  79. Verster A, Buning E: Buprenorphine: Critical Questions Answered. Amsterdam: Quest for Quality BV; 2005.

    Google Scholar 

  80. Lintzeris N, Clark N, Winstock A, et al.: National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Opioid Dependence. Intergovernmental Committee on Drugs (IGCD) subcommittee MaOT ed. Canberra: Australian Department of Health and Ageing; 2006. Recently revised and well-written clinical guidelines for the safe and effective provision of buprenorphine treatment in Australia but with significant relevance for practitioners worldwide.

    Google Scholar 

  81. Center for Substance Abuse Treatment: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction. Treatment Improvement Protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Substance Abuse and Mental Health Services Administration: Rockville, MD; 2004.

    Google Scholar 

  82. Wesson DR, Ling W: The clinical opiate withdrawal scale (COWS). J Psychoactive Drugs 2003, 35:253–259.

    PubMed  Google Scholar 

  83. Fiellin DA, Kleber H, Trumble-Hejduk JG, et al.: Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat 2004, 27:153.

    Article  PubMed  Google Scholar 

  84. Amass L, Bickel WK, Crean JP, et al.: Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology (Berl) 1998, 136:217–225.

    Article  CAS  Google Scholar 

  85. Fiellin DA, Pantalon MV, Chawarski MC, et al.: Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med 2006, 355:365–374.

    Article  PubMed  CAS  Google Scholar 

  86. Baker JR, Best AM, Pade PA, McCance-Katz EF: Effect of buprenorphine and antiretroviral agents on the QT interval in opioid-dependent patients. Ann Pharmacother 2006, 40:392–396.

    Article  PubMed  CAS  Google Scholar 

  87. Bruce RD, Altice FL, Gourevitch MN, Friedland GH: Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 2006, 41:563–572. A review of the literature describing the pharmacokinetic interaction between ARVs and opioid agonist therapies, including methadone and buprenorphine.

    Article  PubMed  CAS  Google Scholar 

  88. McCance-Katz EF, Rainey PM, Friedland G, et al.: Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict 2001, 10:296–307.

    Article  PubMed  CAS  Google Scholar 

  89. McCance-Katz EF, Pade PA, Friedland G, et al.: Efavirenz decreases buprenorphine exposure, but is not associated with opiate withdrawal in opioid dependent individuals [abstract]. In Program and Abstracts of the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.

  90. Iribarne C, Berthou F, Carlhant D, et al.: Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors. Drug Metab Dispos 1998, 26:257–260.

    PubMed  CAS  Google Scholar 

  91. Iribarne C, Picart D, Dreano Y, et al.: Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997, 60:1953–1964.

    Article  PubMed  CAS  Google Scholar 

  92. Decker CJ, Laitinen LM, Bridson GW, et al.: Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998, 87:803–807.

    Article  PubMed  CAS  Google Scholar 

  93. Alford DP, Compton P, Samet JH: Acute pain management for patients receiving maintenance methadone or buprenorphine therapy. Ann Intern Med 2006, 144:127–134. This perspective addresses common misconceptions by providers in managing acute pain in patients receiving opiod agonist therapy and represents a useful, standardized approach to managing acute pain in this setting.

    PubMed  CAS  Google Scholar 

  94. Breitbart W, Rosenfeld BD, Passik SD, et al.: The undertreatment of pain in ambulatory AIDS patients. Pain 1996, 65:243–249.

    Article  PubMed  CAS  Google Scholar 

  95. Olsen Y, Alford DP: Chronic pain management in patients with substance use disorders. Adv Stud Med 2006, 6:111–123.

    Google Scholar 

  96. Malinoff HL, Barkin RL, Wilson G: Sublingual buprenorphine is effective in the treatment of chronic pain syndrome. Am J Ther 2005, 12:379–384.

    Article  PubMed  Google Scholar 

  97. Merrill JO: Integrating medical care and addiction treatment. J Gen Intern Med 2003, 18:68–69.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Positive Health Program, Department of Medicine, University of California, 995 Potrero Avenue, Building 80, Ward 84, San Francisco General Hospital, 94110, San Francisco, CA, USA

    Paula J. Lum MD, MPH

Authors
  1. Paula J. Lum MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacqueline Peterson Tulsky MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paula J. Lum MD, MPH.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lum, P.J., Tulsky, J.P. The medical management of opioid dependence in HIV primary care settings. Curr HIV/AIDS Rep 3, 195–204 (2006). https://doi.org/10.1007/s11904-006-0016-z

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-006-0016-z

Keywords

Search

Navigation